News coverage about Applied Genetic Technologies (NASDAQ:AGTC) has been trending somewhat positive recently, according to Accern Sentiment Analysis. The research firm ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Applied Genetic Technologies earned a news sentiment score of 0.03 on Accern’s scale. Accern also assigned news coverage about the biotechnology company an impact score of 44.4199298656877 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Applied Genetic Technologies (NASDAQ AGTC) traded up $0.15 during mid-day trading on Thursday, hitting $3.90. The stock had a trading volume of 220,500 shares, compared to its average volume of 190,750. The company has a market capitalization of $72.37, a PE ratio of -15.00 and a beta of 1.61. Applied Genetic Technologies has a 12 month low of $3.25 and a 12 month high of $10.15.
A number of analysts have weighed in on the company. Stifel Nicolaus lowered their price target on Applied Genetic Technologies from $15.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday, September 14th. ValuEngine cut Applied Genetic Technologies from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. BMO Capital Markets reiterated an “outperform” rating and issued a $7.00 price target (down from $14.00) on shares of Applied Genetic Technologies in a research report on Thursday, September 14th. HC Wainwright restated a “buy” rating and set a $8.00 target price (down previously from $16.00) on shares of Applied Genetic Technologies in a report on Thursday, September 14th. Finally, Cantor Fitzgerald decreased their target price on Applied Genetic Technologies from $15.00 to $9.00 and set a “neutral” rating on the stock in a report on Thursday, September 14th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company’s stock. Applied Genetic Technologies has an average rating of “Hold” and a consensus price target of $10.17.
ILLEGAL ACTIVITY WARNING: “Applied Genetic Technologies (AGTC) Given Daily Coverage Optimism Score of 0.03” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://transcriptdaily.com/2018/01/04/applied-genetic-technologies-agtc-given-daily-coverage-optimism-score-of-0-03.html.
About Applied Genetic Technologies
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.